BioSyngen is pioneering T-cell immunotherapies to combat various aggressive cancers. Committed to advancing innovative immune-cell therapy technologies, BioSyngen focuses on the clinical and commercial development of cutting-edge treatments aimed at transforming cancer care and improving patient outcomes.
National Ranking1268th
in Singapore Regional Ranking2665th
in South East Asia Global Ranking77332nd
worldwide Rankings by